Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$85.28

-3.18 (-3.59%)

, MYL

Mylan

$28.19

0.14 (0.50%)

14:40
01/24/19
01/24
14:40
01/24/19
14:40

Fly Intel: What to watch in AbbVie earnings report

AbbVie (ABBV) is scheduled to report the results of its fourth fiscal quarter before the market open on January 25, with a conference call scheduled for 9:00 am EDT. What to watch for: 1. 2018 GUIDANCE: With its third quarter report on November 2, AbbVie raised its FY18 adjusted EPS view to $7.90-$7.92 from $7.76-$7.86. At the time of the report, the consensus estimate was $7.88. On the company's Q3 earnings conference call in early November, the drug company said it anticipates Q4 EPS in the range of S $1.89-$1.91 versus a consensus of $1.96. Soon after the earnings report in November, Piper Jaffray analyst Christopher Raymond said he was maintaining a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond said he sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars. 2. LOOKING BEYOND HUMIRA: On October 19, Mylan (MYL) announced that it initiated the commercial launch of Hulio, a biosimilar to AbbVie's Humira, across major markets in Europe. The product, which is approved for all adalimumab indications, will be available to patients as soon as possible, Mylan said in a statement. The European Commission approved Hulio in September. According to an article written by Dan Stanton for BioProcess International, Mike Severino, AbbVie's vice chairman and president, said new product launches will offset any losses from biosimilar competition. "We expect revenue from our non-Humira growth platform, including our durable base business and innovative new products, will grow to more than $35B in 2025", said the AbbVie executive during a recent presentation at the 37th JP Morgan Healthcare Conference. 3. PIPELINE: At a recent conference AbbVie said it expects non-Humira sales to grow more than $35B in 2025. The company noted recently that its portfolio has the potential to address more than 80% of the hematologic malignancies market. On November 21, AbbVie announced that the FDA had granted accelerated approval to Venclexta in combination with azacitidine, or decitabine, or low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. Additionally, on December 20, AbbVie announced that it has submitted a New Drug Application to the FDA and a marketing authorization application to the European Medicines Agency for upadacitinib, an oral investigational JAK1-selective inhibitor, for the treatment of adult patients with moderate to severe rheumatoid arthritis. The NDA and MAA are supported by data from the global upadacitinib SELECT Phase 3 rheumatoid arthritis program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis across five Phase 3 studies. Just last week, AbbVie announced that its Phase 3 study of ibrutinib did not meet its primary endpoint.

ABBV

AbbVie

$85.28

-3.18 (-3.59%)

MYL

Mylan

$28.19

0.14 (0.50%)

  • 25

    Jan

  • 28

    Jan

  • 18

    May

ABBV AbbVie
$85.28

-3.18 (-3.59%)

01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
01/03/19
BOFA
01/03/19
DOWNGRADE
Target $95
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
As noted earlier, BofA/Merrill analyst Jason Gerberry downgraded AbbVie to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality". The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.
01/03/19
01/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Jefferies and Loop Capital, as well as to Neutral from Outperform at Macquarie. 2. Genesee & Wyoming (GWR) downgraded to Equal Weight from Overweight at Stephens with analyst Justin Long citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. 3. Lumber Liquidators (LL) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she reduced her margin forecast to reflect a promotional environment. 4. American Electric (AEP) downgraded to Neutral from Buy at Mizuho with analyst Paul Fremont citing valuation. 5. AbbVie (ABBV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jason Gerberry saying he sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/19
UBSW
01/23/19
INITIATION
Target $91
UBSW
Neutral
AbbVie assumed with a Neutral at UBS
UBS analyst Navin Jacob assumed coverage of AbbVie with an unchanged Neutral rating and lowered his firm's price target for the shares to $91 from $97. While the Humira biosimilar threat has been de-risked, the current valuation offers limited upside, says the analyst.
MYL Mylan
$28.19

0.14 (0.50%)

12/18/18
PIPR
12/18/18
NO CHANGE
Target $400
PIPR
Overweight
Piper says Biogen weakness on Tecfidera patent concerns a buying opportunity
Piper Jaffray analyst Christopher Raymond attributes today's weakness in Biogen (BIIB) shares to a competitor's research note that raised concerns about Mylan's (MYL) IPR challenge of Tecfidera's '514 dosing patent. While acknowledging that a worst case scenario does remove about $50 per share from his sum-of-the-parts valuation for Biogen, Raymond said his read of the current case, along with the fact that the '514 patent previously survived Forward Pharma's 2014 interference claim and Hayman Capital's IPR in 2015, lead him to view such scenario as "very low probability." The analyst, who views the weakness as a buying opportunity, keeps an Overweight rating and $400 price target on Biogen shares, which are down 7% to $291.31 in afternoon trading.
12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
01/23/19
UBSW
01/23/19
DOWNGRADE
Target $32
UBSW
Neutral
Mylan downgraded to Neutral from Buy at UBS
UBS analyst Navin Jacob downgraded Mylan to Neutral and lowered his price target for the shares to $32 from $54 after assuming coverage of the name. The analyst views the stock as "cheap" but sees Street estimates as "overly bullish."
01/23/19
01/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak saying the company's more "tactful messaging" conveys downward pressure to growth expectations and also sees the "realities" of Tesla becoming a volume player highlighting its "challenges to scale and deliver high volume at high ASPs/margins." 2. Lowe's (LOW) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she thinks she was previously too optimistic on Lowe's likely margin progression. 3. Williams-Sonoma (WSM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying he believes top and bottom-line pressures will intensify in 2019. 4. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei citing the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. 5. Pfizer (PFE) and Mylan (MYL) were downgraded to Neutral from Buy at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:35
03/24/19
03/24
19:35
03/24/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GME

GameStop

$10.57

0.03 (0.28%)

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

MAN

Manpower

$80.83

-5.02 (-5.85%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

LYFT

Lyft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 10

    May

  • 12

    Jun

  • 27

    Oct

  • 29

    Mar

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:26
03/24/19
03/24
19:26
03/24/19
19:26
Periodicals
YouTube cancels plans for high-end dramas, comedies, Bloomberg reports »

Google-owned (GOOG;…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 27

    Mar

  • 29

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

ENTG

Entegris

$34.64

-1.2 (-3.35%)

19:23
03/24/19
03/24
19:23
03/24/19
19:23
Hot Stocks
Taiwan court finds Gudeng Precision infringes Entegris' reticle pod patent »

Entegris received an oral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MGTA

Magenta Therapeutics

$18.77

0.805 (4.48%)

19:21
03/24/19
03/24
19:21
03/24/19
19:21
Downgrade
Magenta Therapeutics rating change at Goldman Sachs »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$31.03

-0.05 (-0.16%)

, CMCSA

Comcast

$39.56

-0.49 (-1.22%)

16:20
03/24/19
03/24
16:20
03/24/19
16:20
Hot Stocks
Box Office Battle: 'Us' soars to historic $70M U.S. debut »

Comcast (CMCSA, CMCSK)…

T

AT&T

$31.03

-0.05 (-0.16%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$42.09

-1.915 (-4.35%)

LGF.A

Lionsgate

$15.14

-0.7 (-4.42%)

DIS

Disney

$108.30

-0.36 (-0.33%)

VIAB

Viacom

$25.27

-0.7 (-2.70%)

VIA

Viacom

$30.64

-0.66 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 07

    May

  • 08

    May

  • 20

    May

  • 06

    Jun

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

16:07
03/24/19
03/24
16:07
03/24/19
16:07
Periodicals
Not enough evidence Trump obstructed justice, conspired with Russia, CNBC says »

Attorney General William…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

15:58
03/24/19
03/24
15:58
03/24/19
15:58
Periodicals
Mueller finds no Trump campaign-Russia conspiracy, Reuters reports »

Special Counsel Robert…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$119.21

-3.85 (-3.13%)

15:35
03/24/19
03/24
15:35
03/24/19
15:35
Hot Stocks
Ascendis Pharma announces top-line results from Phase 3 heiGHt trial »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:50
03/24/19
03/24
12:50
03/24/19
12:50
Periodicals
Trump, lawmakers awaiting details of Mueller's report, Reuters says »

U.S. lawmakers drew…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:44
03/24/19
03/24
12:44
03/24/19
12:44
Periodicals
China refusing to concede on U.S. demands to ease curb on tech companies,FT says »

China is refusing to…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$175.60

-5.785 (-3.19%)

12:37
03/24/19
03/24
12:37
03/24/19
12:37
Periodicals
Alibaba acquires Israeli AR startup, Bloomberg reports »

Alibaba has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

12:34
03/24/19
03/24
12:34
03/24/19
12:34
Periodicals
Bayer CEO says team retains backing if supervisory board, Reuters says »

Bayer's management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AAL

American Airlines

$30.60

-0.83 (-2.64%)

, BA

Boeing

$362.15

-10.54 (-2.83%)

12:31
03/24/19
03/24
12:31
03/24/19
12:31
Periodicals
American Airlines extends Boeing 737 Max flight cancellations, Reuters says »

American Airlines (AAL)…

AAL

American Airlines

$30.60

-0.83 (-2.64%)

BA

Boeing

$362.15

-10.54 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

UBER

Uber

$0.00

(0.00%)

12:27
03/24/19
03/24
12:27
03/24/19
12:27
Periodicals
Uber to announce $3.1B deal to buy Careem, Bloomberg says »

Uber is set to announce a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDUS

Radius Health

$18.92

-0.39 (-2.02%)

12:17
03/24/19
03/24
12:17
03/24/19
12:17
Hot Stocks
Radius presents analysis from Phase 3 ACTIVE trial, data from TYMLOS studies »

Radius Health presented a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

13:09
03/23/19
03/23
13:09
03/23/19
13:09
Periodicals
Innovative Industrial Properties flying high, Barron's says »

American cannabis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

13:05
03/23/19
03/23
13:05
03/23/19
13:05
Periodicals
Investors missing how far Caterpillar dug into costs, Barron's says »

Caterpillar has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

MO

Altria Group

$55.90

-0.23 (-0.41%)

12:59
03/23/19
03/23
12:59
03/23/19
12:59
Periodicals
E-cigarettes not helping people quit smoking, Barron's says »

According to the CDC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

MAN

Manpower

$80.83

-5.02 (-5.85%)

, SABR

Sabre

$21.02

-0.62 (-2.87%)

12:51
03/23/19
03/23
12:51
03/23/19
12:51
Periodicals
Sabre, j2 Global among mid-cap stocks with sustainable dividends, Barron's says »

When it comes to…

MAN

Manpower

$80.83

-5.02 (-5.85%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 10

    May

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

, GME

GameStop

$10.57

0.03 (0.28%)

12:47
03/23/19
03/23
12:47
03/23/19
12:47
Periodicals
Gaming meets the cloud as investors scramble to catch up, Barron's says »

The cloud will eventually…

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

GME

GameStop

$10.57

0.03 (0.28%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

LYFT

Lyft

$0.00

(0.00%)

12:42
03/23/19
03/23
12:42
03/23/19
12:42
Periodicals
Investors should avoid booking ride when Lyft goes public, Barron's says »

Lyft will soon be going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DIS

Disney

$108.30

-0.36 (-0.33%)

, AAPL

Apple

$191.11

-3.96 (-2.03%)

12:38
03/23/19
03/23
12:38
03/23/19
12:38
Periodicals
Streaming revolution too complicated, Barron's says »

The streaming revolution…

DIS

Disney

$108.30

-0.36 (-0.33%)

AAPL

Apple

$191.11

-3.96 (-2.03%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 11

    Apr

  • 25

    Apr

  • 08

    May

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.